Scrambler Therapy’s Cancer and Neuropathic Pain Treatment Cleared

February 22, 2021

The latest generation of Scrambler Therapy’s neuropathic and cancer pain treatment has been granted 510(k) marketing clearance by the FDA.

The system, the Scrambler Therapy Technology ST-5A, is indicated for symptomatic relief of chronic opioid-resistant pain and symptomatic relief of chronic cancer and neuropathic pain.

The electro-analgesia therapy uses five artificial neurons to treat severe pain that is not helped by pharmacological and other non-pharmacological treatments. The device replaces its previous two generations, the Calmare and MC-5A, which are no longer being manufactured.

View today's stories